Search

Your search keyword '"Perna, Marco"' showing total 14 results
Start Over Author "Perna, Marco" Publisher elsevier b.v.
14 results on '"Perna, Marco"'

1. Immunogenicity after two and three doses of mRNA vaccine in patients with cancer treated with exclusive radiotherapy

Author

Scoccianti, Silvia, Delli Paoli, Camilla, Infantino, Maria, Paoletti, Lisa, Caini, Saverio, Meacci, Fiammetta, Russo, Serenella, Esposito, Marco, Fondelli, Simona, Grilli Leonulli, Barbara, Grossi, Valentina, Barca, Raffaella, Alpi, Paolo, Furlan, Federica, Perna, Marco, Pino, Maria Simona, Martella, Francesca, Manfredi, Mariangela, Stefanacci, Marco, Bassetti, Andrea, Casprini, Patrizia, and Fioretto, Luisa

Published
2023
Full Text
View/download PDF

2. A predictive model of polymetastatic disease from a multicenter large retrospectIve database on colorectal lung metastases treated with stereotactic ablative radiotherapy: The RED LaIT-SABR study

Author

Nicosia, Luca, Franceschini, Davide, Perrone-Congedi, Francesca, Molinari, Alessandro, Gerardi, Marianna Alessandra, Rigo, Michele, Mazzola, Rosario, Perna, Marco, Scotti, Vieri, Fodor, Andrei, Iurato, Aurelia, Pasqualetti, Francesco, Gadducci, Giovanni, Chiesa, Silvia, Niespolo, Rita Marina, Bruni, Alessio, Cappelli, Anna, D'Angelo, Elisa, Borghetti, Paolo, Di Marzo, Alessandro, Ravasio, Andrea, De Bari, Berardino, Sepulcri, Matteo, Aiello, Dario, Mortellaro, Gianluca, Sangalli, Claudia, Franceschini, Marzia, Montesi, Giampaolo, Aquilanti, Francesco Maria, Lunardi, Gianluigi, Valdagni, Riccardo, Fazio, Ivan, Scarzello, Giovanni, Vavassori, Vittorio, Maranzano, Ernesto, Maria Magrini, Stefano, Arcangeli, Stefano, Gambacorta, Maria Antonietta, Valentini, Vincenzo, Paiar, Fabiola, Ramella, Sara, Di Muzio, Nadia Gisella, Loi, Mauro, Jereczek-Fossa, Barbara Alicja, Casamassima, Franco, Osti, Mattia Falchetto, Scorsetti, Marta, and Alongi, Filippo

Published
2023
Full Text
View/download PDF

3. Local treatment for relapsing glioblastoma: A decision-making tree for choosing between reirradiation and second surgery

Author

Scoccianti, Silvia, Perna, Marco, Olmetto, Emanuela, Delli Paoli, Camilla, Terziani, Francesca, Ciccone, Lucia Pia, Detti, Beatrice, Greto, Daniela, Simontacchi, Gabriele, Grassi, Roberta, Scoccimarro, Erika, Bonomo, Pierluigi, Mangoni, Monica, Desideri, Isacco, Di Cataldo, Vanessa, Vernaleone, Marco, Casati, Marta, Pallotta, Stefania, and Livi, Lorenzo

Published
2021
Full Text
View/download PDF

4. 655: FET-PET and MRI integration in the planning process of HGG treated with adjuvant radiochemotherapy

Author

Paoli, Camilla Delli, Esposito, Marco, Laghai, Iashar, Betti, Margherita, Poggesi, Linda, Meacci, Fiammetta, Alpi, Paolo, Barca, Raffaella, Fondelli, Simona, Leonulli, Barbara Grilli, Paoletti, Lisa, Bruschi, Andrea, Buccoliero, Anna Maria, Muscas, Giovanni, Pratesi, Andrea, Baldazzi, Valentina, Perna, Marco, Konze, Angela, Bartolucci, Maurizio, Puppa, Alessandro Della, Russo, Serenella, Sestini, Stelvio, and Scoccianti, Silvia

Published
2024
Full Text
View/download PDF

5. The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC.

Author

Perna, Marco, Scotti, Vieri, Ciammella, Patrizia, Borghetti, Paolo, D'angelo, Elisa, Levra, Niccolò Giaj, Fozza, Alessandra, Mariotti, Matteo, Salvestrini, Viola, Bertolini, Federica, Vagge, Stefano, Taraborrelli, Maria, Falcinelli, Lorenzo, Taddeo, Alessandra, Rossi, Roberto, Costantino, Gianluca, Frassinelli, Luca, Filippi, Andrea Riccardo, Greco, Carlo, and Franceschini, Davide

Published
2021
Full Text
View/download PDF

6. Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.

Author

Scotti, Vieri, Bruni, Alessio, Francolini, Giulio, Perna, Marco, Vasilyeva, Polina, Loi, Mauro, Simontacchi, Gabriele, Viggiano, Domenico, Lanfranchi, Biancaluisa, Gonfiotti, Alessandro, Topulli, Juljana, Olmetto, Emanuela, Maragna, Virginia, Ferrari, Katia, Bonti, Viola, Comin, Camilla, Balduzzi, Sara, D'Amico, Roberto, Lohr, Frank, and Voltolini, Luca

Published
2019
Full Text
View/download PDF

8. The national COVID-19 vaccination campaign targeting the extremely vulnerable: the Florence Medical Oncology Unit experience in patients with cancer.

Author

Pino, Maria S., Cheli, Simone, Perna, Marco, Fabbroni, Valentina, Giordano, Clara, Martella, Francesca, Lanini, Fabio, Ribecco, Angela S., Scoccianti, Silvia, Bacci, Carlotta, Baldazzi, Valentina, Bertolini, Ilaria, Di Leonardo, Greta, Fulignati, Chiara, Grifoni, Raffaella, Molinara, Elena, Rangan, Sheila, Tassi, Renato, Furlan, Federica, and Goldzweig, Gil

Subjects
*DRUG efficacy, *COVID-19, *PAIN, *FEVER, *CONFIDENCE intervals, *COVID-19 vaccines, *VACCINE refusal, *ACQUISITION of data, *CANCER patients, *MEDICAL records, *ELECTRONIC health records, *LOGISTIC regression analysis, *ODDS ratio, *PATIENT safety, *DRUG toxicity, *EVALUATION
Abstract

International and national oncology societies had released recommendations in favor of COVID-19 vaccination in cancer patients. In the context of the national vaccination campaign targeting the so called extremely vulnerable, we aimed to assess the safety and efficacy of the mRNA vaccines in a cohort of 623 patients. Between March 26 and April 04, 2021, the Pfizer and BioNTech BNT162b2 mRNA and the Moderna mRNA-1273 vaccines were given as a two-dose prime-boost regimen. Starting on September 25th 2021 a third dose was offered to patients in whom a suboptimal immunogenicity with COVID-19 vaccination could be expected. Safety assessments were performed by phone call 7 days after each dose. Electronic health records were accessed to review demographic information, disease history, treatment detail, and outcome events of participants patients'. No toxicities were reported in 63.7%, 54%, and in 48.7% patients with cancer after each dose. Mild-to-moderate pain at the injection site was the most commonly adverse event. After the second dose, 46% of the 610 patients reported toxicity, with more systemic side-effects observed. Fever was reported in 45% of patients, with a temperature ≥ 38 °C in 21.4% of them. Of the 335 patients receiving a third vaccine dose, 51% reported toxicity, with 13% of patients reporting more than one effect. Logistic regression analysis reported mixed results, with limited variables or categories reporting a significant odd ratio. The type of vaccine reported a significant value at first dose (OR = 0.12; CI 0.52, 0.26; p = 0.00). Thirty-four cases of COVID-19 infection were reported with only one patient requiring a short-term hospitalization for monitoring. The safety profile of the mRNA vaccines does not raise any specific concerns and support prioritization of vaccination for cancer patients. • COVID-19 vaccination is recommended in patients with cancer. • We observed a first dose-refusal rate of 4.5%. • No safety concerns have emerged in our cohort of patients. • After two-dose prime-boost vaccination 6 cases of COVID-19 infection were reported. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

9. Systemic treatment of brain metastases in non-small cell lung cancer.

Author

Page, Simon, Milner-Watts, Charlotte, Perna, Marco, Janzic, Urska, Vidal, Natalia, Kaudeer, Naila, Ahmed, Merina, McDonald, Fiona, Locke, Imogen, Minchom, Anna, Bhosle, Jaishree, Welsh, Liam, and O'Brien, Mary

Subjects
*BRAIN tumor treatment, *LUNG cancer & genetics, *LUNG cancer treatment, *LUNG cancer prognosis, *BRAIN tumors, *CANCER chemotherapy, *CELL receptors, *DISEASES, *METASTASIS, *GENETIC mutation, *QUALITY of life, *TUMOR classification, *TREATMENT effectiveness, *EARLY medical intervention, *ENDOTHELIAL growth factors, BRAIN tumor genetics, DIAGNOSIS of brain abnormalities
Abstract

Brain metastases (BrMs) are associated with significant morbidity and are found in up to 50% of patients with advanced non-small cell lung cancer (NSCLC). Most of the literature focuses on symptomatic BrMs, with a lack of baseline brain imaging in asymptomatic patients. Unfortunately, much of the data on local treatments with or without systemic treatment is retrospective. Clinical trials of systemic treatments largely exclude patients with BrMs. Chemotherapy is an active treatment for BrM with response rates in the brain similar to other sites of disease. Targeted systemic treatments in patients with driver mutations (EGFR and ALK-MET to date) have impressive central nervous system (CNS) penetrance and response rates. Unfortunately, no prospective data can currently guide the timings or modality of local therapies with systemic treatments in these patients who have a high incidence of CNS disease, but retrospective data suggest that early local therapies may give better intracranial progression-free survival (ICPFS). Recent immunotherapy trials have included patients with BrMs. These patients have largely been pre-treated with local therapies and are asymptomatic. Thus, the current standard is becoming, early local therapies before or in conjunction with immunotherapy agents. The approach seems to be safe. Prospective studies are needed in NSCLC BrMs patients to make sure any benefit from local therapies on the ICPFS and quality of life is not overlooked. Here we report what we think are reasonable conclusions from the available data and make suggestions for future clinical trials in the management of NSCLC BrMs. • Brain metastases occur in 30% of patients with advanced NSC lung cancer. This percentage can be higher in those with driver mutations. • Whether asymptomatic disease progresses to symptomatic disease is not known. • We do not know if asymptomatic disease should be treated early. • There are many reported series of patients, but most are retrospective with mixed patient populations. • Prospective CTs are needed to ensure we are not missing benefit from addition of local therapy to systemic therapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

10. P2.02-020 Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals: Topic: Clinical Outcome.

Author

Perna, Marco, Scotti, Vieri, Bruni, Alessio, Simontacchi, Gabriele, Di Cataldo, Vanessa, Olmetto, Emanuela, Carta, Giulio Alberto, Grassi, Roberta, Becherini, Carlotta, De Luca Cardillo, Carla, Agresti, Benedetta, Comin, Camilla, Ferrari, Katia, D'Angelo, Elisa, Vasilyeva, Polina, Meduri, Bruno, Lohr, Frank, Voltolini, Luca, and Livi, Lorenzo

Published
2017
Full Text
View/download PDF

12. P2.04-021 Role of Adjuvant Radiotherapy and Prognostic Factor Analysis in Thymic Malignancies: A Retrospective Analysis of 129 Consecutive Patients: Topic: Thymic Malignancies Clinical and Translational.

Author

Bruni, Alessio, Scotti, Vieri, D'Angelo, Elisa, Bastiani, Paolo, Scicolone, Stefano, De Luca Cardillo, Carla, Cecchini, Sara, Perna, Marco, Rubino, Laura, Vasilyeva, Polina, Becherini, Carlotta, Comin, Camilla, Lohr, Frank, and Livi, Lorenzo

Published
2017
Full Text
View/download PDF

13. P3.03-029 EPP Followed by Hemithoracic IMRT - A Multicenter Study on Behalf of the Italian Association for Radiation Oncology Lung Cancer Study Group: Topic: Mesothelioma Clinical.

Author

Trovo, Marco, Franceschini, Davide, Piperno, Gaia, Vagge, Stefano, Scotti, Vieri, De Rose, Fiorenza, Ferrari, Anna Maria, Marcenaro, Michela, Perna, Marco, De Luca Cardillo, Carla, Minatel, Emilio, Jereckzek, Barbara, Scorsetti, Marta, Livi, Lorenzo, and Corvo, Renzo

Published
2017
Full Text
View/download PDF

14. Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy.

Author

Scoccianti, Silvia, Delli Paoli, Camilla, Grilli Leonulli, Barbara, Paoletti, Lisa, Alpi, Paolo, Caini, Saverio, Barca, Raffaella, Fondelli, Simona, Russo, Serenella, Perna, Marco, Pino, Maria Simona, Martella, Francesca, Furlan, Federica, Bassetti, Andrea, and Fioretto, Luisa

Subjects
*COVID-19 vaccines, *CANCER radiotherapy, *CANCER patients
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results